Natera 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Natera processed approximately 1.1 million tests in the 3rd quarter of 2026, up more than 22% from about 894,000 a year ago and a new company record.
- Clinical MRD units reached approximately 316,000, compared with 202,000 in the 3rd quarter of last year, up 56% year over year and approximately 33,000 sequentially.
- Revenue was $794 million, up approximately 34% from $592 million in Q3 of last year and up more than 40% excluding true-ups.
- Reported gross margin was approximately 65%; gross margin excluding true-ups was 63.2%, up about 140 basis points from the 2nd quarter.
- True-ups were about $32 million, down from $52 million in the second quarter; Natera generated cash and narrowed its losses.
- Women's health had mid to high single-digit growth, while organ health volumes grew almost 40% compared with this time last year.
- Signatera ASPs increased to approximately $1,290 from $1,271 in the 2nd quarter.
- Medicare granted coverage for serial use of Signatera in the surveillance setting for patients with early-stage hepatocellular carcinoma.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
I will now hand the conference over to Michael Brophy, Chief Financial Officer. Michael, please go ahead. Thanks, operator.
Good afternoon. Thank you for joining our conference call to discuss the results of our third quarter of 2026. Online, I'm joined by Steve Chapman, Solomon Moshkevich, and Al Solechan. Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be posted to our IR website as soon as it's available. During the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance, such as our operational and financial outlook and projections, our assumptions for that outlook, market size, partnerships, clinical studies, and expected results, opportunities, and strategies and expectations for various current and future products, including product capabilities, expected release dates, reimbursement coverage, and related effects on our financial and operating results.
We caution you that such statements reflect our best judgment based on factors currently known to us, and that actual events or results could differ materially. Please refer to the documents we file from time to time with the SEC, including from our most recent Form 10-K or 10-Q, and the Form 8-K filed with today's press release. Those documents identify important risks and other factors that may cause our actual results to differ materially from those contained in or suggested by the forward-looking statements. Forward-looking statements made during the call are being made as of today, November 5th, 2026. If this call is replayed or reviewed after today, the information presented during the call may not contain current or accurate information. Natera claims any obligation to update or revise any forward-looking statements.
We will provide guidance on today's call, but will not provide any further guidance or updates on our performance during the quarter unless we do so in a public forum. We will quote a number of numeric or growth changes as we discuss our financial performance, and unless otherwise noted, each such reference represents a year-on-year comparison. Now, I'd like to turn the call over to Steve.
Steve? Hi, everyone, and thanks for joining us this afternoon.
As you may have seen by now in the press release, I am stepping down from the CEO role, as now is an excellent time to transition to new leadership for Natera. We've had an incredible run during my time here since joining in 2010. My last almost eight years as CEO have been particularly meaningful to me, and I'm extremely proud of all we've accomplished in that time. Our revenues have increased by roughly tenfold during my tenure as CEO, creating great value for shareholders and having an extraordinary impact on the millions of patients we serve. We've achieved all of that by building an exceptional team who are now in an excellent position to keep executing our plan like we always have. I'm very pleased to be handing the keys over to my friend and colleague, Solomon.
I hired Solomon in 2011, and we shared a small office in those early years of the company as we tried to get our foothold in women's health. Among other accomplishments, he was the key man behind our launch of Prospera for transplant monitoring, and he was the original strategic driver and General Manager for oncology when we were just launching Signatera. Given his leadership of our oncology effort since inception, his breadth of experience across commercial and product-focused roles, and the deep relationships he has across our company, he's uniquely qualified to lead us in our next stage of growth. What's next for me? I'm going to remain engaged as a consultant here with the company and as an advisor to the board, and will be actively involved in making sure Solomon and the team have everything they need to be successful. There's a lot to look forward to.
In the near term, we are on track to launch Signatera in Japan. We have several MolDX submissions underway to expand access for more patients, and we're seeing incredible growth in both clinical and pharma product lines. Next year, we expect to unlock the next major driver for the company and deliver our FDA-enabling FIND study results in early cancer detection. I'm looking forward to staying connected here as we achieve that. Okay. Now, I'm pleased to be the first person to introduce Solomon as the CEO of Natera to take us through the results of an outstanding third quarter.
Solomon? Steve, I accept the handoff with great honor and admiration for what we've accomplished together in the past 15 years under your superb leadership.
When I first joined the company back in 2011, before the launch of Panorama, we were only about 45 people, and as Steve mentioned, he and I shared an office where we could hear each other making cold calls and solving problems for IVF centers around the world. How far we've come. Thank you for your mentorship, and I'm grateful to have your support over the months to come. To everyone, I'm honored to serve as Natera's third CEO. In Natera, we are building an enduring healthcare company, transforming the practice of medicine by enabling earlier, more targeted interventions for those who need it, and by reducing unnecessary treatment for those who do not.
In the coming years, we will improve both treatment and prevention by generating more diagnostic insights from every blood and tissue specimen, developing novel technologies and applying them in entirely new patient populations, integrating more seamlessly at the point of care, and doing it globally. It is a worthy mission, and I am proud to be on it with our 6,500 employees. To all of Natera's employees, clients, partners, investors, and most importantly, to our patients, thank you for your trust. Turning now to the highlights from the quarter. It was an exceptional quarter. We processed approximately 1.1 million tests in the third quarter, up more than 22% from about 894,000 a year ago. Clinical MRD units reached approximately 316,000, compared with 202,000 in the third quarter of last year, for growth of 56%.
That was up about 33,000 units over the second quarter, which makes this the second quarter in a row with more than 30,000 sequential units. Adjusted for the Q1 weather impacts that inflated the Q2 number, I think this is the best quarter we've even had for MRD clinical growth. We generated $794 million in revenue, up approximately 34% over the $592 million that we reported in Q3 of last year. But excluding the true-ups, revenues grew north of 40% year-over-year. Gross margin was approximately 65%, driven by strong organic improvements in both COGS and ASPs. True-ups fell to about $32 million this quarter, down from $52 million in the second quarter. Gross margins held at 65%, but excluding the true-ups, gross margin was at 63.2%, which is up about 140 basis points just from the second quarter.
We generated cash again in the quarter and narrowed our losses significantly, even as we continue to invest aggressively in our future growth. Given the strength of the results, we are raising the revenue guide by approximately $140 million at the midpoint, which means we expect to be above $3 billion for the year. Mike will take you through the specifics of this later in the call. Finally, I'm excited to set a bigger long-term goal for the company. We're setting the goal to double revenues in the next three years, reaching $6 billion in revenue in 2029. I look forward to spending more time on this call to discuss how we'll get there. On the next slide, we'll get into the business trends, starting with overall volumes. I think this chart tells the story well. In the third quarter of 2020, we processed about 262,000 tests.
This quarter, it was about 1.09 million, more than four times that level, and it's a new company record. Obviously, Signatera continues to accelerate, and I'll cover that in a moment, but we were also pleased to see continued growth in women's health and organ health, where women's health posted another strong quarter of mid-to-high single-digit growth, and organ health grew volumes almost 40% compared to this time last year. Driving that growth in women's health is the continued momentum from our product launches, the Fetal Focus late last year, together with the new integrated deep sequencing feature that delivers results at the lowest fetal fractions. In organ transplant monitoring, we're seeing growth coming from the Medicare coverage of surveillance, which was announced in July, and which took effect on August 30th. This has had a positive impact on both volumes and ASPs.
On the oncology front, the next slide shows clinical MRD volumes in more detail. Approximately 316,000 units in the quarter, including both Signatera and Latitude MRD. As I mentioned earlier, this means we added about 33,000 units sequentially versus Q2. You will recall that last year, we made a big push to get the commercial team up to scale that is similar to other specialty diagnostics labs, and those reps were fully onboarded and productive by Q2. Given the number of productive reps in the field was held basically flat, I am particularly pleased to see the volumes continue to ramp. What is driving that growth is that we continue to see excellent increases in both new accounts and new patient starts, as well as continued performance in subsequent repeat testing. This acceleration is happening across tumor types.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
